This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesTrendsBuy This Stock JUNS vs. DERM, MEIP, LXEO, RCEL, ACHV, PROF, AVTX, TARA, CRBP, and SAVAShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include Journey Medical (DERM), MEI Pharma (MEIP), Lexeo Therapeutics (LXEO), Avita Medical (RCEL), Achieve Life Sciences (ACHV), Profound Medical (PROF), Avalo Therapeutics (AVTX), Protara Therapeutics (TARA), Corbus Pharmaceuticals (CRBP), and Cassava Sciences (SAVA). These companies are all part of the "med - drugs" industry. Jupiter Neurosciences vs. Its Competitors Journey Medical MEI Pharma Lexeo Therapeutics Avita Medical Achieve Life Sciences Profound Medical Avalo Therapeutics Protara Therapeutics Corbus Pharmaceuticals Cassava Sciences Journey Medical (NASDAQ:DERM) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Do institutionals & insiders believe in DERM or JUNS? 7.3% of Journey Medical shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor DERM or JUNS? In the previous week, Journey Medical had 4 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 10 mentions for Journey Medical and 6 mentions for Jupiter Neurosciences. Jupiter Neurosciences' average media sentiment score of 0.94 beat Journey Medical's score of 0.57 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jupiter Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate DERM or JUNS? Journey Medical currently has a consensus target price of $11.75, suggesting a potential upside of 57.30%. Given Journey Medical's higher possible upside, research analysts plainly believe Journey Medical is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Jupiter Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is DERM or JUNS more profitable? Jupiter Neurosciences has a net margin of 0.00% compared to Journey Medical's net margin of -15.49%. Journey Medical's return on equity of -48.69% beat Jupiter Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Journey Medical-15.49% -48.69% -11.26% Jupiter Neurosciences N/A -835.24%-155.10% Which has stronger earnings and valuation, DERM or JUNS? Jupiter Neurosciences has lower revenue, but higher earnings than Journey Medical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJourney Medical$56.13M3.24-$14.67M-$0.38-19.66Jupiter Neurosciences$230K230.18-$2.44MN/AN/A SummaryJourney Medical beats Jupiter Neurosciences on 8 of the 14 factors compared between the two stocks. Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.95M$2.54B$5.82B$9.76BDividend YieldN/A1.67%4.40%4.04%P/E RatioN/A22.7131.3826.05Price / Sales230.18752.44472.41122.40Price / CashN/A26.0925.7828.78Price / Book11.695.599.526.07Net Income-$2.44M$31.83M$3.26B$265.39M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$1.52+2.7%N/AN/A$52.95M$230K0.005Earnings ReportAnalyst UpgradeAnalyst RevisionDERMJourney Medical1.6477 of 5 stars$7.00+0.7%$10.83+54.8%+54.7%$163.07M$56.40M-18.4290MEIPMEI Pharma1.096 of 5 stars$4.88-0.2%N/A+58.3%$158.28M$65.30M-1.03100News CoverageAnalyst UpgradeLXEOLexeo Therapeutics2.5422 of 5 stars$4.92+4.2%$15.33+211.7%-59.3%$156.69M$650K-1.5158Analyst RevisionRCELAvita Medical1.42 of 5 stars$5.55-1.4%$12.40+123.4%-47.8%$149.87M$64.25M-2.82130News CoverageACHVAchieve Life Sciences2.2546 of 5 stars$2.66+4.3%$16.00+501.5%-35.3%$130.32MN/A-1.8220News CoveragePositive NewsAnalyst ForecastAnalyst RevisionPROFProfound Medical1.5915 of 5 stars$4.75+11.8%$11.00+131.6%-47.5%$127.73M$10.68M-3.25150Gap DownHigh Trading VolumeAVTXAvalo Therapeutics3.6991 of 5 stars$9.06+0.4%$30.00+231.1%+7.4%$118.63M$440K0.0040TARAProtara Therapeutics1.9832 of 5 stars$3.22+6.3%$19.60+508.7%+43.3%$116.90MN/A-1.9930News CoverageAnalyst RevisionCRBPCorbus Pharmaceuticals4.5008 of 5 stars$9.25flat$49.00+429.7%-83.6%$113.36MN/A-1.9440Positive NewsSAVACassava Sciences2.5214 of 5 stars$2.27-3.0%$2.00-11.9%-92.9%$113.04MN/A-0.8930 Related Companies and Tools Related Companies DERM Competitors MEIP Competitors LXEO Competitors RCEL Competitors ACHV Competitors PROF Competitors AVTX Competitors TARA Competitors CRBP Competitors SAVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access